Welton Amanda J, Vickers Madge R, Kim Joseph, Ford Deborah, Lawton Beverley A, MacLennan Alastair H, Meredith Sarah K, Martin Jeannett, Meade Tom W
MRC General Practice Research Framework, Stephenson House, London NW1 2ND.
BMJ. 2008 Aug 21;337:a1190. doi: 10.1136/bmj.a1190.
To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life.
Randomised placebo controlled double blind trial.
General practices in United Kingdom (384), Australia (94), and New Zealand (24).
Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively.
Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year.
Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiological Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively.
After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and sleep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.001) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year.
Combined HRT started many years after the menopause can improve health related quality of life.
ISRCTN 63718836.
评估联合激素替代疗法(HRT)对健康相关生活质量的影响。
随机安慰剂对照双盲试验。
英国(384个)、澳大利亚(94个)和新西兰(24个)的普通诊所。
随机分组时年龄在50 - 69岁的绝经后女性;3721名有子宫的女性被随机分为联合雌激素和孕激素组(n = 1862)或安慰剂组(n = 1859)。分别有1043名和1087名女性提供了一年时的健康相关生活质量数据。
口服结合马雌激素0.625毫克加醋酸甲羟孕酮2.5/5.0毫克或匹配的安慰剂每日一次,共一年。
通过女性健康问卷测量健康相关生活质量和心理健康。通过症状问卷测量情绪和身体绝经症状的变化,并通过流行病学研究中心抑郁量表(CES - D)测量抑郁情况。分别通过欧洲生活质量量表(EuroQol)和视觉模拟量表测量总体健康相关生活质量和总体生活质量。
一年后,与服用安慰剂的女性相比,服用联合HRT的女性在女性健康问卷的九个组成部分中的三个方面有虽小但显著的改善:血管舒缩症状(P < 0.001)、性功能(P < 0.001)和睡眠问题(P < 0.001)。联合HRT组报告潮热(P < 0.001)、盗汗(P < 0.001)、关节和肌肉疼痛(P = 0.001)、失眠(P < 0.001)和阴道干燥(P < 0.001)的女性明显少于安慰剂组,但报告乳房压痛(P < 0.001)或阴道分泌物(P < 0.001)的比例更高。联合HRT组和安慰剂组在试验开始时潮热发生率分别为30%和29%,一年时分别为9%和25%。一年时在其他绝经症状、抑郁或总体生活质量方面未观察到显著差异。
绝经多年后开始的联合HRT可改善健康相关生活质量。
ISRCTN 63718836。